The Evolving Treatment Paradigm for Upper Tract Urothelial Carcinoma
Saad O Atiq1, Matthew D Galsky2
1Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
None:
Treatment decisions for patients with upper tract urothelial carcinoma (UTUC) require individualized assessments that weigh tumor characteristics, patient factors, and the evidence available. Adjuvant immune checkpoint blockade represents a significant advance in UTUC management, particularly for patients who are ineligible for cisplatin and those with residual disease after neoadjuvant therapy.
More Related Videos
Related Concept Videos
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi III: Medical Management
Kidney Transplant II: Surgical Procedure
Urinary Tract Infection IV: Nursing Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Calculi V: Nursing Management


